TITLE

Lenalidomide

PUB. DATE
December 2007
SOURCE
Reactions Weekly;12/1/2007, Issue 1180, p23
SOURCE TYPE
Periodical
DOC. TYPE
Case Study
ABSTRACT
The article describes the case of a 7-year-old man who developed severe hepatotoxicity, characterised by hyperbilirubinaemia, after receiving lenalidomide for stage IIIB multiple myeloma. The patient had initially received thalidomide and dexamethasone for multiple myeloma. He developed fatigue and peripheral neuropathy. He had significant fatigue and hyperbilirubinaemia following treatment with oral lenalidomide, dexamethasone, prophylactic warfarin and aspirin for venous thromboembolism.
ACCESSION #
27874511

 

Related Articles

  • Lenalidomide.  // Reactions Weekly;11/28/2009, Issue 1280, p31 

    The article describes the case of a 67-year-old man who developed hepatotoxicity during treatment with lenalidomide for multiple myeloma. The patient presented with jaundice, fatigue and vomiting, which started during his second 3-week course of oral lenalidomide and dexamethasone. His...

  • VTE did not affect survival in lenalidomide/dexamethasone-treated multiple myeloma.  // Hem/Onc Today;12/10/2009, Vol. 10 Issue 23, p64 

    The article discusses research which compared the effects of lenalidomide plus high-dose dexamethasone against dexamethasone plus placebo in multiple myeloma patients who developed venous thromboembolism, conducted by M. Zangari, published in a 2009 issue of the "Journal of Clinical Oncology."

  • Lenalidomide.  // Reactions Weekly;2/20/2016, Vol. 1589 Issue 1, p138 

    An abstract of the article "Clinical analysis of thromboembolism associated with lenalidomide based regimens for multiple myeloma patients" by X. Qu and others is presented.

  • Thalidomide-induced severe hepatotoxicity. Dabak, Vrushali; Kuriakose, Philip // Cancer Chemotherapy & Pharmacology;Mar2009, Vol. 63 Issue 4, p583 

    The article focuses on the impact of thalidomide, the drug of choice for erythema nodosum leprosum on medicine. Thalidomide was introduced as a sedative agent and was found to alleviate symptoms of morning sickness. It was approved by the Food and Drug Administration (FDA) for use in combination...

  • Aspirin, warfarin may reduce thromboembolic events in multiple myeloma.  // Hem/Onc Today;3/25/2011, Vol. 12 Issue 6, p14 

    The article reports that fixed-dose warfarin or aspirin showed comparable efficiency as low-molecular-weight heparin in cutting the risk for thromboembolic events in myeloma patients who received regimens with thalidomide, which is based on a study involving 659 patients.

  • Aspirin for VTE prophylaxis in multiple myeloma questioned.  // Reactions Weekly;8/24/2013, Issue 1466, p4 

    An abstract of the article "MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs," by X. Leleu is presented.

  • Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Palumbo, A.; Davies, F.; Kropff, M.; Bladé, J.; Delforge, M.; Costa, F. Leal Da; Garcia Sanz, R.; Schey, S.; Facon, T.; Morgan, G.; Moreau, P. // Annals of Hematology;Aug2010, Vol. 89 Issue 8, p803 

    Thalidomide has received approval from the European Agency for the Evaluation of Medicinal Products for the treatment of newly diagnosed multiple myeloma (MM) patients older than 65 years or ineligible for transplant. The results of five phase III trials assessing thalidomide in combination with...

  • Thromboprophylaxis with LMWH, warfarin, low-dose aspirin, safe in newly diagnosed multiple myeloma.  // Hem/Onc Today;1/10/2010, Vol. 11 Issue 1, p18 

    This article focuses on a study which investigated the efficacy and safety of thromboprophylaxis with low-molecular weight heparin, warfarin or low-dose aspirin in preventing venous thromboembolism in patients with multiple myeloma.

  • Physical activity participation and barriers for people with multiple myeloma. Craike, Melinda; Hose, Kaye; Livingston, Patricia // Supportive Care in Cancer;Apr2013, Vol. 21 Issue 4, p927 

    Purpose: This study aims to examine, for people treated for multiple myeloma, (1) differences between prediagnosis and postdiagnosis levels of physical activity, (2) perceived barriers and likelihood of attending a physical activity program, and (3) factors that influence whether or not...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics